Q-omics provides the consensus-scored UBE2I profile across patient tissues and cancer cell-line models. UBE2I expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2I is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, UBE2I RNA expression shows 18,389 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, HNSC, and KIRP as cancer lineages where UBE2I shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2I — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2I survival associations across molecular data types. UBE2I RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2I RNA expression–survival associations across cancer types. High UBE2I expression shows unfavorable associations in LIHC, PAAD and LGG, but favorable associations in COAD, UVM and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2I RNA expression.
This table summarizes UBE2I tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE2I. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2I shows higher tumor expression in HNSC, KIRC, KIRP, COAD, THCA and LIHC. The HNSC box plot shows higher UBE2I RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with UBE2I in patient tissues and cancer cell lines. In patient samples, UBE2I shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2I RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
